MedTrace Logo

Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains

NCT05213910 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 189

Last updated 2022-04-06

No results posted yet for this study

Summary

The aim of this study is to determine the impact of a 10-day treatment with Lactichoc® on irritable bowel syndrome.

Conditions

  • Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

Lactichoc

dosage form: mix of 8 strains containing 1.2x10\^11 CFU frequency, and duration: 2 capsules/day during 10 days

OTHER

Stool sampling

3 stool samples are taken during the study (D0, D10 and D30)

Sponsors & Collaborators

  • PiLeJe

    lead INDUSTRY

Principal Investigators

  • Dominique DELSART

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-04
Primary Completion
2021-11-15
Completion
2021-11-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05213910 on ClinicalTrials.gov